• Ygalo Continues to Induce Clinically Meaningful Responses in Relapsed or Refractory Multiple Myeloma, Phase 1/2 Trials Show
  • Early Data Show Positive Activity of Iberdomide Against Heavily Treated MM
  • AMG 420 Immunotherapy Effective in Difficult-to-treat Multiple Myeloma, Early Study Results Show
  • Clinical Trial Results Suggest Isatuximab Improves Survival in People with RRMM
  • Similar Efficacy and Safety Seen Between Under-the-Skin Formulation and Intravenous Darzalex for Myeloma, Phase 3 Trial Shows
  • FDA Grants Priority Review to Darzalex Combo for Transplant-eligible Patients
  • CAR T-Cell Candidate bb2121 Shows Promising Signs of Safety and Efficacy for Relapsed or Refractory Myeloma, Interim Data Show
  • Pivotal OPTIMISMM Trial Shows Benefits of Pomalyst Triple Combo Therapy
  • Open Enrollment for Phase 1 Trial Testing CS1-CAR T-Cell Therapy for Hard-to-Treat Myeloma
  • Oncopeptides Prepares NDA for Accelerated Approval of Ygalo as Treatment for Refractory Multiple Myeloma
  • Revlimid Becomes Option for First-line Multiple Myeloma Treatment in England
  • Therapy for Heavily Treated Multiple Myeloma Gets Fast Track Status from FDA